WHO End TB Strategy and Global Tuberculosis Targets
Tuberculosis (TB) remains a major public-health challenge requiring sustained diagnosis, treatment, prevention and community support. The WHO End TB Strategy sets global milestones, while India’s National Tuberculosis Elimination Programme (NTEP) aligns national action with these goals.
WHO End TB Strategy and Global Targets
Adopted by the World Health Assembly in 2014, the WHO End TB Strategy aims to end the global TB epidemic by 2035. It contributes to Sustainable Development Goal (SDG) 3, particularly target 3.3, which calls for ending the epidemics of AIDS, TB, malaria and neglected tropical diseases by 2030. The strategy uses 2015 as the baseline for its reduction targets.
| Milestone year | Reduction in TB deaths | Reduction in TB incidence rate |
| 2020 | 35% | 20% |
| 2025 | 75% | 50% |
| 2030 | 90% | 80% |
| 2035 | 95% | 90%; fewer than 10 cases per 100,000 population |
The strategy rests on three pillars:
- Integrated, patient-centred care and prevention: Early diagnosis, universal drug-susceptibility testing and systematic screening.
- Bold policies and supportive systems: Political commitment, adequate resources, and engagement with communities and civil society.
- Intensified research and innovation: Development and rapid uptake of improved tools and interventions.
Understanding Tuberculosis
TB is an infectious disease caused primarily by Mycobacterium tuberculosis. It most often affects the lungs, but may also affect organs such as the lymph nodes, bones, kidneys and brain. It spreads through airborne particles released when a person with infectious TB coughs, sneezes or speaks.
- Latent TB infection: TB bacteria are present but inactive; the person has no symptoms and is not infectious.
- Active TB disease: The bacteria multiply, cause illness and may be transmitted to others.
- Drug-resistant TB: Resistance develops when TB bacteria are no longer susceptible to medicines used for treatment.
- MDR-TB: Multidrug-resistant TB is resistant to at least isoniazid and rifampicin, two key anti-TB drugs.
India’s National Tuberculosis Elimination Programme
The National Tuberculosis Elimination Programme, formerly the Revised National Tuberculosis Control Programme (RNTCP), aims to eliminate TB in India by 2025—five years before the global SDG deadline. It provides free, quality diagnosis and treatment through the government health system. Domestic resources meet 96% of the programme’s funding requirements. NTEP operates through national, state, district and sub-district levels, with Tuberculosis Units at block level. Its diagnostic network has three tiers: frontline microscopy and rapid molecular testing; intermediate reference and culture laboratories; and national reference laboratories responsible for quality assurance. CBNAAT (Cartridge Based Nucleic Acid Amplification Test) and TruNat are rapid molecular tests used to diagnose TB and detect rifampicin resistance, an important indicator of drug resistance. Key programme interventions include:
- Case finding: Proactive identification and community-based screening campaigns.
- Technology: AI-enabled X-rays to support detection, alongside rapid molecular diagnostics.
- Digital monitoring: The Ni-kshay portal supports case notification and patient management.
- Nutritional assistance: Ni-kshay Poshan Yojana provides registered TB patients ₹1,000 per month throughout treatment. The benefit was increased from ₹500 per month in November 2024 and is transferred to Aadhaar-linked bank accounts through Direct Benefit Transfer.
Community Support and TB Elimination
The Pradhan Mantri TB Mukt Bharat Abhiyaan was launched by the President of India on 9 September 2022. It seeks to strengthen community participation, improve awareness, reduce stigma, provide additional patient support and improve nutritional outcomes. Such support can also help reduce families’ out-of-pocket expenditure. The Abhiyaan’s Ni-kshay Mitra initiative encourages individuals and institutions to support TB patients with nutrition, diagnostic assistance and vocational support for at least one year. From 7 December 2024 to 8 November 2026, the campaign screened over 25 crore people, conducted more than 11 crore chest X-rays and over 3 crore nucleic acid amplification tests. It identified 48.64 lakh new cases, including 14.97 lakh asymptomatic cases.
Implementation and Global Health Governance
India’s 2025 elimination target is more ambitious than the global SDG deadline, but progress must be assessed against incidence, mortality, treatment outcomes and access to care. The scale of TB and drug resistance makes sustained domestic financing, reliable surveillance and equitable access to diagnosis and treatment important. Global health governance also depends on international cooperation, shared research and the timely adoption of effective tools. Community engagement complements public-health services by supporting screening, treatment and nutrition.
Key Prelims Takeaways
- The WHO End TB Strategy was adopted in 2014 and sets a 2035 global target.
- Its reduction milestones use 2015 as the baseline; the 2025 targets are 75% fewer deaths and 50% lower incidence.
- SDG target 3.3 calls for ending the TB epidemic by 2030.
- NTEP was formerly known as RNTCP; India set a national elimination target of 2025.
- CBNAAT and TruNat are rapid molecular tests used for TB diagnosis and rifampicin-resistance detection.
- Ni-kshay Poshan Yojana provides ₹1,000 per month to registered TB patients during treatment.
- Ni-kshay Mitra operates under the Pradhan Mantri TB Mukt Bharat Abhiyaan.
Recent Context
The WHO Global Tuberculosis Report 2026, released on 12 November, confirmed that India missed its 2025 elimination target. Indian TB deaths fell 38% between 2015 and 2025, exceeding the global decline of 35%, but remaining short of the strategy’s 2025 mortality target.